Timothy J. Voorhees, The Ohio State University, Columbus, OH
Eric M. McLaughlin, The Ohio State University, Columbus, OH
Pallawi Torka, Memorial Sloan Kettering Cancer Center, New York, NY
Jorge Florindez, University of North Carolina, Chapel Hill, NC
Na Hyun Kim, Medical College of Wisconsin Cancer Center, Milwaukee, WI
Tamara K. Moyo, Levine Cancer Institute, Charlotte, NC
Heather Reves, University of Texas Southwestern Medical Center, Dallas, TX
Nuttavut Sumransub, University of Minnesota, Minneapolis, MN
Saarang Deshpande, University of Pennsylvania, Philadelphia, PA
Ashley Rose, Moffitt Cancer Center, Tampa, FL
Cassandra Duarte, University of Colorado Cancer Center, Aurora, CO
Muhammad Salman Faisal, Roswell Park Comprehensive Cancer Center, Buffalo, NY
Showkat Hamid, Roswell Park Comprehensive Cancer Center, Buffalo, NY
Suki Subbiah, LSU Health Sciences Center - New OrleansFollow
Sabarish Ayyappan, University of Iowa, Iowa City, IA
Lauren Shea, University of Alabama at Birmingham, Birmingham, AL
Matt Cortese, Roswell Park Comprehensive Cancer Center, Buffalo, NY
Krish Patel, Swedish Cancer Institute, Seattle, WA
Ajay Major, University of Colorado Cancer Center, Aurora, CO
Hayder Saeed, Moffitt Cancer Center, Tampa, FL
Jakub Svoboda, University of Pennsylvania, Philadelphia, PA
Sanjal Desai, University of Minnesota, Minneapolis, MN
Praveen Ramakrishnan Geethakumari, University of Texas Southwestern Medical Center, Dallas, TX
Mehdi Hamadani, Medical College of Wisconsin Cancer Center, Milwaukee, WI
Natalie Grover, University of North Carolina, Chapel Hill, NC
Narendranath Epperla, University of Utah, Salt Lake City, UT

Document Type

Article

Publication Date

3-26-2025

Publication Title

Blood Cancer Journal

Abstract

Anti-PD-1 based therapies and brentuximab vedotin (BV) have significantly improved survival in patients with classic Hodgkin lymphoma (cHL) and have been incorporated into earlier lines of therapy. However, there is insufficient data regarding the clinical outcomes in patients who develop refractory disease or who become intolerant of BV and anti-PD-1 therapies (double refractory/intolerant; DR/INT). Here, we evaluated outcomes in patients with DR/INT cHL from 15 US academic medical centers. A total of 173 patients were identified as DR/INT. The median overall survival from the time of cHL diagnosis (OS-1) was 14.8 years (95% CI: 10.9–20.9 years) and the 10-year OS-1 estimate was 62% (95% CI: 52–70%). After accounting for differences in age, patients who underwent autologous stem cell transplant prior to developing DR/INT had significantly longer OS-1 (HR 0.53, 95% CI: 0.29–0.96, p = 0.04). Median OS from time of DR/INT (OS-2) was 7.4 years (95% CI: 4.3-NR) and the 5-year OS-2 estimate was 57% (95% CI: 48-66%). Both anti-PD-1 and BV based therapy rechallenge were effective with median PFS of 237 days (95% CI: 155-357 days) and 183 days (95% CI: 108–273 days), respectively. Finally, advanced therapy options such as CD30 directed chimeric antigen receptor T-cell therapy and allogeneic stem cell transplant after DR/INT were associated with improved OS-2 (p < 0.001). To our knowledge, this represents the largest cohort of patients with DR/INT cHL. OS-2 will serve as a benchmark for future studies aiming to improve survival in DR/INT cHL.

PubMed ID

40140364

Volume

15

Issue

1

Download

Share

COinS